Affiliations: Medicina Nucleare e Radiodiagnostica, Istituto Nazionale dei Tumori, Naples, Italy
via Raffaele De Cesare 7, Naples 80132, Italy
Ctr. Med. Nucl. Cons. Naz. Ric., Univ. degli Studi Federico II, Naples, Italy
Boland, G.W., Goldberg, M.A., Lee, M.J., Indeterminate adrenal mass in patients with cancer: Evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose (1995) Radiology, 194, pp. 131-134
Erasmus, J.J., Patz E.F., Jr., McAdams, H.P., Evaluation of adrenal masses in patients with bronchogenic carcinoma using F-18 fluorodeoxyglucose positron emission tomography (1997) AJR, 168, pp. 1357-1360
Sundin, A., Juhlin, C., Bonasera, T., Lu, L., Langstrom, B., Bergstrom, M., C-11 metomidate PET imaging and characterization of adrenal tumors (1997) Radiology, 205 (P), p. 400
Rigo, P., Paulus, P., Kaschten, B.J., Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose (1996) Eur J Nucl Med, 23, pp. 1641-1674
Shulkin, B.L., Koeppe, R.A., Francis, I.R., Deeb, G.M., Lloyd, R.V., Thompson, N.W., Pheochromocytomas that do not accumulate metaiodobenzylguanidine: Localization with PET and administration of FDG (1993) Radiology, 186, pp. 711-715
Minn, H., Joensuu, H., Ahonen, A., Klemi, P., Fluorodeoxyglucose imaging: A method to assess the proliferative activity of human cancer in vivo -comparison with DNA flow cytometry in head and neck tumors (1988) Cancer, 61, pp. 1776-1778
Gross, M. D., Shapiro, B., Clinical review 50: Clinically silent adrenal masses (1993) J Clin Endocrinol Metab, 77, pp. 885-88
Ross, M. S., Aron, D. C., Hormonal evaluation of the patient with an incidentally discovered adrenal mass (1990) N Engl J Med, 323, pp. 1402-1405
Francis, I. R., Gross, M. D., Shapiro, B., Integrated imaging of adrenal disease (1992) Radiology, 184, pp. 1-13
Lee, M. J., Mayo-Smith, W. W., Hahn, P. F., State-of-the-art MR imaging: Imaging of the adrenal gland (1994) RadioGraphics, 14, pp. 1015-1029
Boland, G. W., Goldberg, M. A., Lee, M. J., Indeterminate adrenal mass in patients with cancer: Evaluation at PET with 2- [F-18] -fluoro-2-deoxy-D-glucose (1995) Radiology, 194, pp. 131-134
Erasmus, J. J., Patz E. F., Jr., McAdams, H. P., Evaluation of adrenal masses in patients with bronchogenic carcinoma using F-18 fluorodeoxyglucose positron emission tomography (1997) AJR, 168, pp. 1357-1360
Shulkin, B. L., Koeppe, R. A., Francis, I. R., Deeb, G. M., Lloyd, R. V., Thompson, N. W., Pheochromocytomas that do not accumulate metaiodobenzylguanidine: Localization with PET and administration of FDG (1993) Radiology, 186, pp. 711-715
Characterization of adrenal tumors using F-18 FDG PET imaging: Comparison between benign and malignant lesions
OBJECTIVE. The aim of this study was to differentiate benign from malignant adrenal tumors using positron emission tomography (PET) with 18F- fluorodeoxyglucose (FDG) in patients with unilateral adrenal masses originally detected by CT or MR imaging. CONCLUSION. PET imaging with FDG can metabolically characterize adrenal masses. Abnormally increased FDG uptake in adrenal malignancies allows one to differentiate these abnormalities from benign lesions. Whole-body PET can also reveal extraadrenal tumor sites in patients with malignant tumors, using a single imaging technique for accurate disease staging.
Characterization of adrenal tumors using F-18 FDG PET imaging: Comparison between benign and malignant lesions
No results.
Characterization of adrenal tumors using F-18 FDG PET imaging: Comparison between benign and malignant lesions